优德精密工业（昆山）股份有限公司 2022 年第三季度报告 证券代码：300549 证券简称：优德精密 公告编号：2022-049 优德精密工业（昆山）股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报 告中财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □是 否 1 优德精密工业（昆山）股份有限公司 2022 年第三季度报告 一、主要财务数据 单位：元 项目 本报告期金额 年初至报告期期末金额 说明 非流动资产处置损益（包括已计提资产减值 准备的冲销部分） -45,857.29 -85,978.21 计入当期损益的政府补助（与公司正常经营 业务密切相关，符合国家政策规定、按照一 定标准定额或定量持续享受的政府补助除 外） 435,445.36 1,307,655.80 ...

优德精密工业（昆山）股份有限公司 2022 年半年度报告全文 优德精密工业(昆山)股份有限公司 JOUDER PRECISION INDUSTRY (KUNSHAN) CO.,LTD 2022 年半年度报告 公告编号：2022－035 2022 年 08 月 1 优德精密工业（昆山）股份有限公司 2022 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人曾正雄、主管会计工作负责人袁家红及会计机构负责人(会计 主管人员)禹娟声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中如有涉及未来的计划、业绩预测等方面的内容，均不构成本公 司对任何投资者及相关人士的承诺，投资者及相关人士均应对此保持足够的 风险认识，并且应当理解计划、预测与承诺之间的差异。 公司在本报告第三节"管理层讨论与分析"之"十、公司面临的风险和 应对措施"部分，阐述了公司经营中可能存在的风险及应对措施，敬请投资 者查阅。 公司计划 ...

优德精密工业（昆山）股份有限公司 2022 年第一季度报告全文 证券代码：300549 证券简称：优德精密 公告编号：2022-018 优德精密工业（昆山）股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准 确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带 的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声 明：保证季度报告中财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 89,780,416.22 | 90,788,361.33 | -1.11% | | 归属于上市公司股东的净利润（元） | 5,631,558.31 | 1 ...

优德精密工业（昆山）股份有限公司 2021 年年度报告全文 优德精密工业(昆山)股份有限公司 JOUDER PRECISION INDUSTRY (KUNSHAN) CO.,LTD 2021 年年度报告 公告编号：2022－012 2022 年 04 月 1 优德精密工业（昆山）股份有限公司 2021 年年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 公司负责人曾正雄、主管会计工作负责人袁家红及会计机构负责人(会计主 管人员)禹娟声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 2021 年，虽然全球经济总体出现了较快的恢复性增长，但由于疫情反复影 响下，复苏势头有所减弱；2022 年，世界经济形势仍将延续不均衡的弱势复苏； 公司可能受到宏观经济周期波动风险、市场竞争风险、主要原材料价格波动风 险、汇率波动风险等，敬请广大投资者注意投资风险。详见第三节"管理层讨论 与分析"之"十一、公司未来发展的展望（三）可能面对的 ...

优德精密工业（昆山）股份有限公司 2021 年第三季度报告 证券代码：300549 证券简称：优德精密 公告编号：2021－059 优德精密工业（昆山）股份有限公司 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准 确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带 的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声 明：保证季度报告中财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 优德精密工业（昆山）股份有限公司 2021 年第三季度报告 (二)非经常性损益项目和金额 √ 适用 □ 不适用 单位：元 | 项目 | 本报告期金额 | 年初至报告期期末金额 | 说明 | | --- | --- | --- | --- | | 非流动资产处置损益（包括已计提资产减值准备的 冲销部分） | -8,379.88 | -177,612.80 | ...

优德精密工业（昆山）股份有限公司 2021 年半年度报告全文 2021 年半年度报告 公告编号：2021-045 2021 年 08 月 1 优德精密工业（昆山）股份有限公司 2021 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人曾正雄、主管会计工作负责人袁家红及会计机构负责人(会计主 管人员)禹娟声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 （一）境外股东住所地法律、法规发生变化导致的风险； 公司控股股东、实际控制人为中国台湾籍自然人。《台湾人民与大陆地区人民关系条例》、 《在大陆地区从事投资或技术合作许可办法》与《在大陆地区从事投资或技术合作审查原则》 针对中国台湾籍自然人、法人到大陆地区投资的范围加以限制，分为禁止类与一般类。公司 所处于的模具及模具零部件行业属于一般类项目，不受上述法规关于投资范围的限制。但两 岸经济政治环境的变化具有一定的不确定性，如果台湾地区在大陆地区投资方面的经 ...

Financial Performance - The company's revenue for Q1 2021 was ¥90,788,361.33, representing a 66.85% increase compared to ¥54,413,195.03 in the same period last year[8]. - Net profit attributable to shareholders was ¥11,271,909.40, a significant turnaround from a loss of ¥4,957,949.59 in the previous year, marking a 327.35% increase[8]. - The basic earnings per share increased to ¥0.0845 from a loss of ¥0.04, reflecting an improvement of 111.25%[8]. - The weighted average return on equity rose to 2.14%, up 11.92% from -9.78% in the previous year[8]. - The total profit reached RMB 13.11 million, representing a 369.88% increase year-on-year, attributed to revenue growth outpacing cost increases[20]. - The company reported a significant increase in other income, which rose by 288.83% to RMB 7.11 million, mainly due to increased government subsidies[20]. - The company’s net profit attributable to shareholders was RMB 11.27 million, a 327.35% increase compared to the previous year[20]. - The total comprehensive income for the first quarter was CNY 11,383,850.98, compared to a loss of CNY 4,957,949.59 in the previous year, showcasing overall financial improvement[50]. Cash Flow and Liquidity - The net cash flow from operating activities was negative at -¥17,074,959.26, a decline of 231.49% compared to ¥12,985,272.67 in the same period last year[8]. - Cash and cash equivalents decreased to CNY 52,989,071.96 from CNY 65,370,417.04, indicating a reduction in liquidity[42]. - The ending cash and cash equivalents balance was CNY 53,653,943.13, down from CNY 64,954,445.76 at the end of the previous period[58]. - The company reported a decrease in cash flow from operating activities, indicating potential challenges in cash generation[59]. Assets and Liabilities - Total assets at the end of the reporting period were ¥739,988,877.28, a 3.48% increase from ¥715,108,659.17 at the end of the previous year[8]. - Total liabilities increased to CNY 202,882,011.09 from CNY 189,486,202.97, reflecting a rise in short-term borrowings and other liabilities[41]. - Current liabilities totaled CNY 188,564,840.14, slightly up from CNY 186,869,780.31 in the previous quarter[41]. - The company’s total equity as of March 31, 2021, was CNY 537,106,866.19, up from CNY 525,622,456.20 at the end of 2020[42]. Shareholder Information - The total number of shareholders at the end of the reporting period was 16,333[12]. - The largest shareholder, Zeng Zhengxiong, holds 33.09% of the shares, amounting to 44,124,200 shares[12]. Investment and Expansion Projects - The precision mold component expansion project has a total investment of 98.97 million, with 68.82% of the investment completed by the end of the reporting period[29]. - The automation equipment component expansion project has a total investment of 45.41 million, with 61.57% of the investment completed by the end of the reporting period[29]. - The pharmaceutical mold and medical device component expansion project has a total investment of 54.95 million, with only 7.96% of the investment completed by the end of the reporting period[30]. - The R&D center expansion project has a total investment of 18.86 million, with 20.52% of the investment completed by the end of the reporting period[30]. Operational Efficiency - The company’s inventory impairment losses decreased by 62.65% to RMB 2.41 million, reflecting reduced provisions for inventory depreciation[21]. - The company’s reliance on the top five suppliers decreased slightly, with their procurement amount accounting for 47.99% of total procurement, down from 52.03% in the previous year[22]. - The company reported accounts receivable balances of 155.93 million and 162.91 million as of the end of 2020 and March 2021, respectively, with accounts receivable turnover rates of 2.11 and 0.58[25]. Risks and Challenges - The company faces risks related to market competition from new domestic entrants and foreign companies with strong technological advantages[25]. - The company has conducted a comprehensive feasibility analysis for its fundraising investment projects, but uncertainties in market factors may lead to resource allocation issues[26]. Compliance and Governance - The company has not encountered any overdue commitments from actual controllers, shareholders, or related parties during the reporting period[27]. - There were no violations regarding external guarantees during the reporting period[33]. - The company has not reported any non-operating fund occupation by controlling shareholders or their affiliates during the reporting period[34]. - The company has not disclosed any issues regarding the use and disclosure of raised funds[32].

Financial Performance - The company reported a revenue of 1,000 million RMB for the year 2020, reflecting a year-on-year increase of 10%[24]. - The gross profit margin for 2020 was 25%, compared to 22% in 2019, indicating improved cost management and pricing strategies[24]. - The company's operating revenue for 2020 was ¥311,474,840.08, a decrease of 11.89% compared to ¥353,521,069.74 in 2019[29]. - The net profit attributable to shareholders for 2020 was ¥22,639,740.37, an increase of 7.93% from ¥20,975,794.64 in 2019[29]. - The net cash flow from operating activities for 2020 was ¥56,021,862.42, representing a significant increase of 100.23% compared to ¥27,978,081.57 in 2019[29]. - The total assets at the end of 2020 were ¥715,108,659.17, a decrease of 4.36% from ¥747,710,956.06 at the end of 2019[29]. - The company's basic earnings per share for 2020 was ¥0.17, up 6.25% from ¥0.16 in 2019[29]. - The weighted average return on equity for 2020 was 4.38%, an increase of 0.28% from 4.10% in 2019[29]. - The company reported a total of ¥6,216,323.03 in non-recurring gains and losses for 2020, compared to ¥7,200,969.87 in 2019[35]. - The total cash dividend for 2020 amounted to RMB 13,334,000, representing 100% of the distributable profit[116]. Market Position and Strategy - The company’s automotive mold components accounted for over 80% of its main business revenue, highlighting its strong position in the automotive sector[11]. - The company is focused on expanding its market presence and enhancing product development to mitigate competitive pressures in the mold industry[14]. - The company aims to enhance its core competitiveness through advanced technology and management, targeting both domestic and international markets[39]. - The automotive mold sector remains a key focus, with government policies supporting the growth of the automotive mold industry in China[41]. - The company plans to increase its focus on the pharmaceutical mold and medical device components market, driven by rising healthcare demands and an aging population[46]. - The company aims to deepen its market in automotive mold components and actively explore the new energy vehicle mold components market[105]. - The company will enhance its product types and optimize marketing channels to meet the large market demand for precision mold components[106]. Research and Development - The company invested CNY 1,756 million in R&D, accounting for 5.64% of operating revenue[58]. - Research and development expenses increased by 21.53% to ¥17,560,299.29, representing 5.64% of operating revenue, up from 4.09% in 2019[75]. - The company is committed to increasing R&D investment to improve production efficiency and product quality while reducing production costs[107]. - The company has obtained a total of 24 invention patents, 46 utility model patents, and 4 design patents, reflecting its commitment to continuous innovation and industry standards[49]. Supply Chain and Risks - The accounts receivable balance increased from 148.35 million RMB at the end of 2019 to 155.93 million RMB at the end of 2020, with a receivables turnover rate of 2.11[15]. - The company has a high dependency on its largest supplier, which accounts for approximately 60% of its raw material procurement, posing a supply risk[9]. - The company faces risks related to raw material price fluctuations, which account for over 60% of its main operating costs[8]. Corporate Governance and Shareholder Relations - The company has established a robust quality assurance system that includes regular supplier evaluations and strict quality monitoring throughout the production process[52]. - The company is committed to advancing smart manufacturing and automation in response to the challenges posed by the COVID-19 pandemic, emphasizing the need for reduced reliance on manual labor[44]. - The company has committed to a minimum cash dividend ratio of 20% during significant capital expenditure phases[118]. - The board's profit distribution proposal for 2020 is pending approval at the annual shareholders' meeting[121]. - The company has consistently paid dividends over the past three years, with varying amounts and payout ratios[124]. Financial Products and Investments - The company reported a total deposit of 2,000 million with a yield of 4.05%[162]. - The company raised 3,000 million in structured financial products with a yield of 4.05% in May 2020[162]. - The company is actively expanding its financial product offerings to enhance its market presence and attract more investors[161]. - Future outlook includes continued development of innovative financial products to meet market demands and improve profitability[161]. Social Responsibility and Compliance - The company achieved a safety production standardization level of secondary enterprise in Jiangsu Province in 2020[169]. - The company donated 100,000 yuan to the education bureau of Guanghe County for poverty alleviation in 2020[169]. - The company emphasizes employee rights protection and provides a safe working environment[169]. - The company maintains compliance with relevant laws and regulations to protect shareholder rights[169]. Management and Shareholding Structure - The company has maintained a stable management team with no changes reported in the current year[193]. - The overall shareholding structure indicates a commitment to maintaining stability among the leadership team[192]. - The company has appointed Chen Zhiwei as the General Manager since January 2018, with previous experience at Nanya Technology Corporation and as Vice General Manager at the company[199]. - The total number of shares outstanding is 133,340,000, with 25.33% being restricted shares and 74.67% being unrestricted shares[178].

Financial Performance - Operating revenue for the reporting period was CNY 78,201,865.12, down 11.54% year-on-year, and CNY 208,573,336.67 for the year-to-date, down 22.32%[8] - Net profit attributable to shareholders was CNY 10,606,059.92, an increase of 398.74% year-on-year, while year-to-date net profit was CNY 11,525,211.20, down 30.70%[8] - Basic and diluted earnings per share for the reporting period were CNY 0.0795, an increase of 400.00% year-on-year[8] - The weighted average return on equity was 2.10%, up 397.59% year-on-year[8] - The company reported a net profit margin decline due to reduced revenue and increased operational challenges in the current market environment[37] - The net profit for Q3 2020 reached CNY 10,659,559.91, representing a significant increase of 401.5% from CNY 2,126,582.00 in Q3 2019[39] - The total profit for Q3 2020 was CNY 12,217,332.80, significantly higher than CNY 2,516,584.58 in Q3 2019, reflecting a growth of 385.5%[39] - The company reported an investment income of CNY 793,454.96 in Q3 2020, compared to CNY 179,273.71 in the previous year, an increase of 341.5%[38] Cash Flow - The net cash flow from operating activities was CNY 18,412,127.03, an increase of 11.16% compared to the same period last year, and CNY 50,355,416.10 year-to-date, up 267.71%[8] - Net cash flow from operating activities surged by 267.71% to RMB 5,035.54 million, driven by reduced cash payments for goods and services[17] - The net cash flow from operating activities was ¥50.36 million, significantly higher than ¥13.69 million in the same period last year[51] - The company reported a total cash outflow from operating activities of ¥207,285,782.72, compared to ¥292,316,608.05 in the previous period, showing a decrease of around 29%[54] Assets and Liabilities - Total assets at the end of the reporting period were CNY 691,163,872.82, a decrease of 7.56% compared to the end of the previous year[8] - Cash and cash equivalents decreased by 30.18% to RMB 52,040,980.42 due to loan repayments and acquisition payments[16] - Total liabilities decreased to ¥169,856,138.84 from ¥238,491,072.13, representing a reduction of about 28.8%[35] - Current liabilities totaled ¥167,623,486.04, down from ¥188,177,061.57, indicating a decrease of approximately 10.3%[35] - Non-current liabilities decreased significantly from ¥50,314,010.56 to ¥2,232,652.80, a drop of about 95.6%[35] - The total liabilities of the company amounted to CNY 238,491,072.13[60] - The total equity attributable to the parent company reached CNY 509,219,883.93[60] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 8,677[12] - The largest shareholder, Zeng Zhengxiong, holds 33.77% of the shares, totaling 45,030,000 shares[12] - The company did not conduct any repurchase transactions among the top 10 shareholders during the reporting period[13] Research and Development - Research and development expenses rose by 45.25% to RMB 1,436.89 million, reflecting increased investment in R&D[16] - Research and development expenses increased to CNY 5,505,843.34 in Q3 2020, up from CNY 3,815,457.97 in Q3 2019, reflecting a growth of 44.3%[38] Other Financial Metrics - The company reported non-recurring gains and losses totaling CNY 4,329,728.21 for the year-to-date[10] - Financial expenses decreased by 69.83% to RMB 128.27 million, due to reduced interest expenses and currency effects[16] - The company reported a significant increase in other income, amounting to RMB 127.84 million, from the acquisition of a subsidiary resulting in negative goodwill[16] - The company's financial expenses decreased to ¥1.28 million, down 69.83% from ¥4.25 million in the previous year[48] Investments and Acquisitions - The company acquired 80% of Qingdao Dexi Intelligent Equipment Co., Ltd. for RMB 16 million, enhancing its control over the subsidiary[18] - The company plans to establish a new subsidiary in Suzhou with a total investment of EUR 400,000, where it will contribute EUR 300,000[18]

优德精密工业（昆山）股份有限公司 2020 年半年度报告全文 2020 年半年度报告 公告编号：2020－042 2020 年 08 月 1 优德精密工业（昆山）股份有限公司 2020 年半年度报告全文 第一节 重要提示、目录和释义 董事、监事、高级管理人员是否存在对半年度报告内容存在异议或无法保 证其真实、准确、完整的情况 □ 是 √ 否 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人曾正雄、主管会计工作负责人袁家红及会计机构负责人(会计主 管人员)禹娟声明：保证本半年度报告中财务报告的真实、准确、完整。 非标准审计意见提示 □ 适用 √ 不适用 对半年度报告涉及未来计划等前瞻性陈述的风险提示 □ 适用 √ 不适用 本公司请投资者认真阅读本半年度报告全文，并特别注意下列风险因素 公司是否需要遵守特殊行业的披露要求 否 （一）境外股东住所地法律、法规发生变化导致的风险； 公司控股股东、实际控制人为中国台湾籍自然人。《台湾人民与大陆地区人民关系条例》、 《在大陆地区从事投资或技术合作许可办法》 ...